Briquilimab

Monoclonal antibody

Ungradedevidence

Evidence outlook

Mid- and late-stage studies completed

This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (2)
Other / comorbidity
NCT05907746 · National Cancer Institute (NCI)
2023-11-29 – 2028-07-31 · GATA2, Immunodeficiency
What this study did
NCT06736262 · Jasper Therapeutics, Inc.
2024-11-26 – 2026-07-21 · Urticaria Chronic
What this study did
Phase 1/2 (6)
Chronic Spontaneous Urticaria
Other / comorbidity
NCT04784052 · Porteus, Matthew, MD
2021-12-07 – 2028-12 · Fanconi Anemia
What this study did
NCT06145282 · National Heart, Lung, and Blood Institute (NHLBI)
2023-12-28 – 2027-11-26 · Sickle Cell Disease
What this study did
NCT05357482 · National Heart, Lung, and Blood Institute (NHLBI)
2022-05-12 – 2027-01-31 · Sickle Cell Anemia, Beta Thalassemia
What this study did
NCT02963064 · Jasper Therapeutics, Inc.
2017-03-20 – 2025-07-07 · SCID
What this study did
Phase 1 (4)
Asthma
Other / comorbidity
NCT05600907 · National Institute of Allergy and Infectious Diseases (NIAID)
2023-01-02 – 2036-11-30 · Chronic Granulomatous Disease, CGD
What this study did
NCT05903274 · Jasper Therapeutics, Inc.
2023-06-19 – 2024-10-21 · Lower-risk Myelodysplastic Syndrome
What this study did
NCT04429191 · Jasper Therapeutics, Inc.
2020-07-08 – 2023-06-13 · MYELODYSPLASTIC SYNDROME; MDS, ACUTE MYELOID LEUKEMIA; AML
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, 3 of them ahead of this one.

This drug's own stage for Chronic Spontaneous Urticaria: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Briquilimab: this drugPhase 1/2Monoclonal antibodyKITnot yet gradedNo reviewed efficacy summary in this indication
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
Omalizumab (Xolair)ApprovedMonoclonal antibodyIgE (immunoglobulin E), IgEPartial signal
NCT01287117: Change From Baseline to Week 12 in the Weekly Itch Severity Score (Baseline to Week 12): Placebo -3.63 Units on a scale (Standard Deviation 5.22) | Omalizumab 75 mg -6.46 Units on a scale (Standard Deviation 6.14) | Omalizumab 150 mg -6.66 Units on a scale (Standard Deviation 6.28) | Omalizumab 300 mg -9.4 Units on a scale (Standard Deviation 5.73)
NCT01292473: Change in weekly itch severity score at week 12 vs placebo (-5.14): omalizumab 75 mg -5.87, difference -0.69 (95% CI -2.54 to 1.16), p=0.4637; 150 mg -8.14, difference -3.04 (95% CI -4.85 to -1.24), p=0.0011; 300 mg -9.77, difference -4.81 (95% CI -6.49 to -3.13), p<0.0001 (CT.gov posted results).
RemibrutinibApprovedSmall moleculeBruton's tyrosine kinase (BTK)Reliable signalNo reviewed efficacy summary in this indication
BarzolvolimabPhase 3Monoclonal antibodyKITPartial signal
NCT06445023: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22).
NCT06455202: Primary endpoint met: mean change from baseline in weekly urticaria activity score (UAS7) at Week 12 vs placebo; all key secondary endpoints also met (Celldex, 2026-09-22).
Bezuclastinib
Phase 3(overall)
Small moleculeKIT
not yet graded(overall)
No reviewed efficacy summary in this indication
Velzatinib
Phase 3(overall)
Small moleculeKIT
not yet graded(overall)
No reviewed efficacy summary in this indication
AK139Phase 2Multispecific antibodyIL-4 receptor alpha / ST2not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
HRS-3095Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
Girocitinib
—(overall)
Small moleculeTYK2/JAK1Reliable signalNo reviewed efficacy summary in this indication
SAR449028
—(overall)
UndisclosedKITnot yet gradedNo reviewed efficacy summary in this indication
SHR-3095
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Briquilimab to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
Phase 1/2Fanconi AnemiaRecruiting
Est. primary completion 2027-12 · NCT04784052 · CT.gov ↗
What to watch
2036 (1)
November 2036 (1)
Phase 1Chronic Granulomatous Disease, CGDActive not recruiting
Est. primary completion 2036-11-30 · NCT05600907 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 January 2026Topline resultUpdated BEACON and open label extension data for briquilimab in CSU